Silexion Therapeutics closed at $0.15 on Nov 4, up 0.10%, 99.6% below its 52-week closing high. Volume of 129.1K shares was 0.09× its 20-day average (below normal).
Split-adjusted performance: -41.6% over one month, -97.3% over six months, -99.5% over one year.
Short interest was 162.7K shares at the Oct 15 settlement, down 96.7% from the prior report (3.7% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SLXNSilexion Therapeutics | $0.1535 | +0.10% | −97.3% | — | — | — | $2.2M | |
| VIVSVivoSim Labs | $0.1522 | +5.99% | −89.2% | −51.4% | −7433.3% | — | $2.0M | Compare |
| CLDICalidi Biotherapeutics | $0.7299 | −2.54% | −79.3% | — | — | — | $1.9M | Compare |
| CRISCuris | $1.11 | +55.48% | −91.0% | −100.0% | — | — | $2.7M | Compare |
| HLSQTessera Defense and Homeland Security | $0.1440 | −1.57% | — | — | — | — | $3.0M | Compare |
| LIMNLiminatus Pharma | $2.79 | +0.16% | −72.7% | — | — | — | $3.8M | Compare |
| PMCBPharmaCyte Biotech | $0.3810 | +12.03% | −50.5% | — | — | — | $4.1M | Compare |
| CELZCreative Medical Technology Holdings | $0.6519 | −3.21% | −70.8% | — | — | — | $4.9M | Compare |
| AIMAIM ImmunoTech | $0.1610 | +0.19% | −66.5% | +4.0% | −26876.9% | — | $6.4M | Compare |
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
